Adherence to long-term adjuvant hormonal therapy for breast cancer

被引：0

作者：

Gotay, Carolyn ^{[1
]}

Dunn, Julia ^{[1
]}

机构：

[1] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2011年 / 11卷 / 06期

关键词：

adherence; aromatase inhibitors; breast cancer; tamoxifen; LOW-INCOME WOMEN; AROMATASE INHIBITORS; ENDOCRINE THERAPY; EARLY DISCONTINUATION; TAMOXIFEN; COHORT; NONADHERENCE; PERSISTENCE; PREVENTION; PREDICTORS;

D O I：

10.1586/ERP.11.80

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Tamoxifen is an essential drug in treating hormone receptor-positive breast cancer and has been used successfully for the past three decades. More recently, aromatase inhibitors (AIs) have also shown great promise in reducing breast cancer recurrence. To receive the optimal benefits, patients need to take these drugs for a period of 5 years. Yet, despite the known positive patient outcomes associated with their use, adherence to both tamoxifen and AIs is substantially less than ideal. This article reviews the most recent literature reporting adherence rates for tamoxifen and AIs, as well as correlates of adherence. Factors that help to explain nonadherence are reviewed, including the side-effect profile, and approaches to intervention to enhance adherence are discussed.

引用

页数：7

共 50 条

[11] Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer
Abderrahman, Balkees
Jordan, V. Craig
[J]. JAMA ONCOLOGY, 2017, 3 (02) : 163 - 164
[12] Long-term follow-up of a randomized trial on adjuvant chemotherapy and hormonal therapy in locally advanced breast cancer
Koning, C
Hart, G
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (02): : 397 - 400
[13] Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence
Pourcelot, Charlotte
Orillard, Emeline
Nallet, Gilles
Dirand, Camille
Billion-Rey, Francois
Barbier, Garance
Chouk, Sarah
Limat, Samuel
Montcuquet, Philippe
Henriques, Julie
Paget-Bailly, Sophie
Anota, Amelie
Chaigneau, Loic
Nerich, Virginie
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (01) : 153 - 162
[14] Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence
Charlotte Pourcelot
Emeline Orillard
Gilles Nallet
Camille Dirand
François Billion-Rey
Garance Barbier
Sarah Chouk
Samuel Limat
Philippe Montcuquet
Julie Henriques
Sophie Paget-Bailly
Amélie Anota
Loïc Chaigneau
Virginie Nerich
[J]. Breast Cancer Research and Treatment, 2018, 169 : 153 - 162
[15] Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer
Bekele, Firomsa
[J]. PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 2845 - 2846
[16] What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?
Aron Goldhirsch
Richard D Gelber
Alan S Coates
[J]. Nature Clinical Practice Oncology, 2005, 2 : 440 - 441
[17] What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?
Goldhirsch, A
Gelber, RD
Coates, AS
[J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (09): : 440 - 441
[18] Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Hormone Receptor Positive Breast Cancer
Ward, K. A.
Muller, D. A.
Dutta, S. W.
Malhi, J.
Sanders, J.
Luminais, C.
Millard, T. A.
Showalter, T. N.
Showalter, S.
Janowski, E. M.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E216 - E216
[19] Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy
Manfred Kaufmann
Achim Rody
[J]. Journal of Cancer Research and Clinical Oncology, 2005, 131 : 487 - 494
[20] Is long-term adjuvant endocrine therapy for breast cancer an over-treatment?
Hoelzel, D.
Schubert-Fritschle, G.
Engel, J.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 49 - 49

← 1 2 3 4 5 →